Juncture Wealth Strategies’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-11,599
| Closed | -$430K | – | 118 |
|
|
2023
Q4 | $430K | Sell |
11,599
-1,300
| -10% | -$46.7K | 0.2% | 81 |
|
|
2023
Q3 | $468K | Buy |
12,899
+1,200
| +10% | +$42.6K | 0.23% | 83 |
|
|
2023
Q2 | $417K | Sell |
11,699
-2,001
| -15% | -$71.8K | 0.2% | 93 |
|
|
2023
Q1 | $487K | Buy |
13,700
+3,500
| +34% | +$122K | 0.24% | 77 |
|
|
2022
Q4 | $358K | Sell |
10,200
-4,200
| -29% | -$140K | 0.17% | 84 |
|
|
2022
Q3 | $424K | Buy |
14,400
+2,858
| +25% | +$108K | 0.21% | 75 |
|
|
2022
Q2 | $628K | Sell |
11,542
-138
| -1% | -$7.62K | 0.31% | 56 |
|
|
2022
Q1 | $636K | Sell |
11,680
-160
| -1% | -$8.69K | 0.3% | 65 |
|
|
2021
Q4 | $653K | Sell |
11,840
-80
| -0.7% | -$4.16K | 0.31% | 64 |
|
|
2021
Q3 | $569K | Buy |
11,920
+1,040
| +10% | +$52.2K | 0.3% | 65 |
|
|
2021
Q2 | $553K | Sell |
10,880
-640
| -6% | -$30.8K | 0.32% | 69 |
|
|
2021
Q1 | $524K | Buy |
11,520
+720
| +7% | +$32.7K | 0.33% | 67 |
|
|
2020
Q4 | $497K | Hold |
10,800
| – | – | 0.31% | 71 |
|
|
2020
Q3 | $508K | Buy |
10,800
+1,280
| +13% | +$64.1K | 0.35% | 63 |
|
|
2020
Q2 | $485K | Sell |
9,520
-80
| -0.8% | -$4.1K | 0.37% | 62 |
|
|
2020
Q1 | $455K | Buy |
9,600
+2,000
| +26% | +$107K | 0.42% | 53 |
|
|
2019
Q4 | $446K | Buy |
7,600
+1,200
| +19% | +$66.8K | 0.35% | 72 |
|
|
2019
Q3 | $341K | Buy |
6,400
+1,760
| +38% | +$90.5K | 0.3% | 79 |
|
|
2019
Q2 | $232K | Buy |
+4,640
| New | +$233K | 0.19% | 103 |
|
|
2017
Q4 | – | Sell |
-5,360
| Closed | -$272K | – | 85 |
|
|
2017
Q3 | $272K | Hold |
5,360
| – | – | 0.15% | 80 |
|
|
2017
Q2 | $289K | Buy |
5,360
+80
| +2% | +$4.26K | 0.17% | 77 |
|
|
2017
Q1 | $278K | Sell |
5,280
-1,520
| -22% | -$77.1K | 0.17% | 74 |
|
|
2016
Q4 | $327K | Buy |
6,800
+400
| +6% | +$19.8K | 0.23% | 73 |
|
|
2016
Q3 | $345K | Buy |
6,400
+720
| +13% | +$39.5K | 0.23% | 69 |
|
|
2016
Q2 | $308K | Buy |
5,680
+80
| +1% | +$4.21K | 0.22% | 66 |
|
|
2016
Q1 | $284K | Sell |
5,600
-240
| -4% | -$12K | 0.21% | 72 |
|
|
2015
Q4 | $295K | Sell |
5,840
-2,080
| -26% | -$106K | 0.22% | 72 |
|
|
2015
Q3 | $381K | Sell |
7,920
-3,040
| -28% | -$158K | 0.31% | 66 |
|
|
2015
Q2 | $571K | Sell |
10,960
-960
| -8% | -$54.1K | 0.46% | 52 |
|
|
2015
Q1 | $688K | Sell |
11,920
-12,146
| -50% | -$696K | 0.57% | 42 |
|
|
2014
Q4 | $1.3M | Buy |
+24,066
| New | +$1.35M | 0.62% | 42 |
|
Other funds holding GSK
JEST
Juncture Wealth Strategies's GSK Position: Q1 2024 in Review
Juncture Wealth Strategies sold out of GSK (GSK) in Q1 2024, closing a stake of 11,599 shares — an estimated $430K sold.
Juncture Wealth Strategies first reported a position in GSK in Q4 2014 and held it in 31 quarters. The position peaked at $1.3M in Q4 2014. 910 funds tracked by Wall St. Rank hold GSK as of Q1 2024.
- Juncture Wealth Strategies reported no remaining GSK position as of Q1 2024 after selling out during the quarter.
- Juncture Wealth Strategies sold 11,599 GSK shares in Q1 2024, an estimated $430K.
- Juncture Wealth Strategies first reported a position in GSK in Q4 2014 and held it in 31 quarters.
- Juncture Wealth Strategies's GSK position peaked at $1.3M in Q4 2014.
- 910 funds tracked by Wall St. Rank held GSK as of Q1 2024.
Based on Juncture Wealth Strategies's 13F filing for Q1 2024, filed 5 Apr 2024.